Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 39% Improvement Relative Risk Ventilation 5% Hospitalization time -1% Flisiak et al. Molnupiravir for COVID-19 EARLY Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 590 patients in Poland (January - April 2022) Lower mortality with molnupiravir (p=0.034) Flisiak et al., Pharmacological Reports, doi:10.1007/s43440-022-00408-6 Favors molnupiravir Favors control
Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
Flisiak et al., Pharmacological Reports, doi:10.1007/s43440-022-00408-6 (date from earlier preprint)
Flisiak et al., Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance, Pharmacological Reports, doi:10.1007/s43440-022-00408-6 (date from earlier preprint)
Jul 2022   Source   PDF  
  All Studies   Meta
Retrospective 590 patients in Poland, 203 treated with mulnupiravir, showing lower mortality with treatment.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson,] for analysis of variants potentially created by molnupiravir.
risk of death, 39.5% lower, RR 0.61, p = 0.03, treatment 20 of 203 (9.9%), control 63 of 387 (16.3%), NNT 16.
risk of mechanical ventilation, 4.7% lower, RR 0.95, p = 1.00, treatment 7 of 203 (3.4%), control 14 of 387 (3.6%), NNT 591.
hospitalization time, 0.9% higher, relative time 1.01, p = 0.96, treatment mean 11.6 (±7.9) n=203, control mean 11.5 (±9.3) n=387.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Flisiak et al., 6 Jul 2022, retrospective, Poland, peer-reviewed, 13 authors, study period 1 January, 2022 - 30 April, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: Pharmacological Reports SPECIAL ISSUE: ARTICLE The Post-COVID Era - Advances and Challenges in Pharmacology Real‑world experience with molnupiravir during the period of SARS‑CoV‑2 Omicron variant dominance Robert Flisiak1 · Dorota Zarębska‑Michaluk2,3 · Magdalena Rogalska1 · Justyna Anna Kryńska1 · Justyna Kowalska4 · Ewa Dutkiewicz5,6 · Krystyna Dobrowolska2 · Jerzy Jaroszewicz7 · Anna Moniuszko‑Malinowska8 · Marta Rorat9 · Regina Podlasin10 · Olga Tronina11 · Piotr Rzymski12 Received: 28 June 2022 / Revised: 12 August 2022 / Accepted: 17 August 2022 © The Author(s) 2022 Abstract Background The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections. Methods Among 11,822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 31 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons. Results Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups. Conclusions The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age. Keywords Molnupiravir · COVID-19 · SARS-CoV-2 · Omicron · Treatment · Real-world experience Robert Flisiak and Dorota Zarębska-Michaluk contributed equally. * Robert Flisiak 1 2 Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15‑540, ul. Żurawia 14, Białystok, Poland Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland 3 Provincial Hospital, Kielce, Poland 4 Department of Adults’ Infectious Diseases, Medical University of Warsaw, Warsaw, Poland 5 ZOZ, Busko Zdroj, Poland 6 Jan Kochanowski University, Collegium Medicum, Kielce, Poland 7 Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland 8 Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, Białystok, Poland 9 Department of Forensic Medicine, Wrocław Medical University, Wrocław, Poland 10 IV‑th Department, Hospital for Infectious Diseases, Warsaw, Poland 11 Department of Transplantation Medicine, Nephrology, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland 12 Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop